Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Capital Cell is Europe's first dedicated life sciences equity crowdfunding platform, founded in 2015 in Barcelona, Spain by CEO Daniel Oliver. The organization specializes in democratizing access to high-impact investments in the life sciences sector, allowing individuals to contribute to advancements in human health. The platform operates under the European Crowdfunding Service Providers (ECSP) regulation, enabling it to function across multiple European markets.
As of 2024, Capital Cell has facilitated over 120 funding rounds, deploying approximately €107 million across its portfolio of companies. The firm has established a significant presence in the biotech investment landscape, particularly in Spain, where it accounts for an estimated 40-50% of early-stage biotech investments. The firm also has a secondary office in Cambridge, UK, which was opened in 2017 to attract UK investors.
Capital Cell's unique approach combines equity crowdfunding with a rigorous vetting process through its BioExpert Network, which consists of over 800 opinion leaders and biomedical experts. This network enhances the credibility of the startups listed on the platform, ensuring that investors are presented with thoroughly vetted opportunities. The firm has achieved notable milestones, including significant exits such as Bionure, which signed a billion-dollar licensing agreement in 2021.
Capital Cell focuses on investing in biotechnology and life sciences companies through equity crowdfunding. The firm primarily targets early-stage investments, including pre-seed, seed, and seed+ (extension) rounds. The investment strategy emphasizes a rigorous due diligence process, leveraging its BioExpert Network to ensure that only the most promising startups are presented to investors.
The sectors of interest include biotech, healthcare, medical devices, and diagnostics. Capital Cell aims to connect private investors with high-impact opportunities in these fields, allowing them to participate in funding rounds that were traditionally accessible only to institutional investors. The platform's check sizes vary by company, but it allows minimum investments starting at €100, making it accessible to a broad range of investors.
Geographically, Capital Cell operates primarily in Europe, with a strong focus on Spain and an expanding presence in the UK and other European markets. The firm’s investment thesis centers on democratizing access to biotech investments, thereby enabling a diverse pool of investors to support innovative health solutions.
As of 2024, Capital Cell has completed over 120 funding rounds, with a total investment of approximately €107 million across more than 120 companies. The portfolio includes notable companies such as:
Other active portfolio companies include those developing intraocular devices and oxygen monitoring solutions for preterm infants. The firm has facilitated over 104 investment rounds, with a reported multiplier of 3.19 times the initial investment value across its portfolio, showcasing the potential for significant returns.
Daniel Oliver - CEO and co-founder of Capital Cell, Daniel Oliver has a background in biology and is an alumnus of IE University. He founded Capital Cell after recognizing the funding gap for biotech startups compared to digital startups. With over a decade of experience in biotech investment, he serves as the primary public face of the firm and has been actively involved in discussions about the biotech investment landscape.
Capital Cell's operations are supported by its BioExpert Network, which includes over 800 opinion leaders and biomedical experts who assist in the due diligence process. This network is a critical asset for the firm, enhancing the credibility of the startups listed on the platform.
Startups interested in pitching to Capital Cell should submit their proposals through the official website. The firm prefers detailed decks that clearly outline the business model, market opportunity, and scientific validation. Founders should include information about their team, product development stage, and any preliminary data or traction.
While specific response times are not disclosed, startups can expect a thorough review process due to the firm's selective nature. Warm introductions are beneficial but not mandatory. Capital Cell encourages founders to be clear and concise in their communications to facilitate a smoother evaluation process.
In November 2023, Capital Cell's CEO Daniel Oliver was interviewed by Seedblink, discussing the current state of the biotech investment landscape and the firm's role in democratizing access to biotech investments. The firm has also announced a strategic partnership with SeedBlink to enhance financing opportunities for European tech startups in biotech and healthtech.
As of 2023, Capital Cell has facilitated over 104 investment rounds, raising more than €53 million across its platform. The firm continues to expand its presence in Spain and the UK, aiming to capture a larger share of the early-stage biotech investment market.
What are Capital Cell's investment criteria?
Capital Cell invests in early-stage biotechnology and life sciences companies, focusing on pre-seed, seed, and seed+ rounds. The firm emphasizes a rigorous vetting process through its BioExpert Network, which consists of over 800 biomedical experts who evaluate each investment opportunity.
How can startups apply or pitch to Capital Cell?
Startups interested in raising capital through Capital Cell can apply via their website. The platform has a selective acceptance rate of approximately 3%, ensuring that only the most promising companies are considered for funding.
What makes Capital Cell different from traditional venture capital firms?
Capital Cell operates as an equity crowdfunding platform specifically for biotech and life sciences, allowing individual investors to participate in funding rounds. This model democratizes access to investments that were previously limited to institutional investors, while also providing startups with validation from a network of biomedical experts.
What is the geographic scope of Capital Cell's investments?
Capital Cell primarily invests in European biotech startups, with a strong focus on Spain and an expanding presence in the UK and other European markets. The firm aims to support innovative health solutions across the continent.
What is the typical check size for investments?
While individual campaign check sizes are not specified, Capital Cell allows minimum investments starting at €100, making it accessible to a wide range of investors. The total amount raised varies by company and funding round.
What kind of post-investment involvement does Capital Cell have?
Capital Cell provides access to its BioExpert Network for portfolio companies, offering scientific due diligence and support. This enhances the credibility of the startups and helps them navigate the challenges of growth and development in the biotech sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.